×
About 18,710 results

Study of Difluprednate Ophthalmic Emulsion in the Treatment of Uveitis
https://clinicaltrials.gov/ct2/show/NCT00406887

Dec 3rd, 2006 - The objective of this phase 3 study is to assess the efficacy and safety of 0.05% difluprednate ophthalmic emulsion (DFBA) in patients with endogenous anterior uveitis, in comparison with 0.1% betamethasone sodium phosphate ophthalmic solution (BP).

Study of Safety and Efficacy of an Oral Contraceptive
https://clinicaltrials.gov/ct2/show/NCT00477633

Apr 21st, 2013 - This is a non-comparative study. the primary objective of the study is to assess the efficacy of a low dose oral contraceptive in the prevention of pregnancy. The secondary objectives are to assess the incidence of intracyclic bleeding; and to assess the safety and tolerability of the product.

Fat Metabolites and Gut Hormones
https://clinicaltrials.gov/ct2/show/NCT03223389

Jul 25th, 2017 - Dietary triglycerides are hydrolyzed during digestion to two fatty acids and one 2-monoacyl glycerol. The study will investigate the effects of these different fat components on gut hormone secretion in gastric bypass operated patients and non-operated BMI-matched controls.

Hormone Replacement Therapy and the Risk of Breast Cancer Recurrence in Women With Previous Early Stage Breast Cancer
https://clinicaltrials.gov/ct2/show/NCT00003771

Sep 19th, 2013 - OBJECTIVES: Evaluate the safety of hormone replacement therapy, in terms of risk of recurrence, in women with previously treated, nonrecurrent stage 0-II breast cancer. Compare this regimen vs non-hormonal symptomatic treatment, in terms of quality of life and risk of death, in this patient population. OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified by cent...

Combination Chemotherapy With or Without PSC 833 in Treating Patients With Relapsed or Refractory Multiple Myeloma
https://clinicaltrials.gov/ct2/show/NCT00002878

Aug 28th, 2013 - OBJECTIVES: Compare the overall survival and objective response rate of patients with relapsed or refractory multiple myeloma treated with vincristine, doxorubicin, and dexamethasone (VAD) with or without PSC 833. Compare event free survival and subjective response in patients treated with these regimens. Correlate treatment outcome with p-glycoprotein expression. Determine whether prognostic f...

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension
https://clinicaltrials.gov/ct2/show/NCT02338960

Oct 1st, 2018 - This will be a multicenter, randomized, placebo-controlled, parallel group study in up to 80 sites in the United States of America (USA) and Canada to evaluate the efficacy and safety of a fixed dose of SC BMT versus placebo on an as-needed basis under conditions of home use in premenopausal women with HSDD (with or without decreased arousal). The study will consist of 2 phases: (1) a 32-week p...

Efficacy of Nonsteroidal Anti-inflammatory Drugs in Treatment of Moderate and Severe Dry Eye Disease
https://clinicaltrials.gov/ct2/show/NCT01562795

Jan 2nd, 2014 - This clinical trial is to investigate whether nonsteroid anti-inflammatory drops have therapeutic effect on moderate to severe dry eye patients.And compare the efficacy of the two nonsteroid anti-inflammatory drops with topical corticosteroids.

Adding Liraglutide to High Dose Insulin: Breaking the Cycle
https://clinicaltrials.gov/ct2/show/NCT01505673

Jan 15th, 2018 - Type 2 diabetes is a progressive disease with incessant beta-cell dysfunction that often ultimately requires insulin treatment. Patients requiring high insulin dosages represent a particular treatment challenge and often have uncontrolled glycemia despite progressive dose increases and are especially prone to insulin related lipotoxicity and weight gain. Glucagon-like peptide agonists (GLP-1) s...

Antimullerian Hormone as an Indicator for Ovarian Response
https://clinicaltrials.gov/ct2/show/NCT03291860

Sep 24th, 2017 - Anti Mullerian hormone (AMH) is gaining place as ovarian marker, chiefly in infertility assistance. Investigators explored its correlation with oocytes retrieval after long GnRH agonist protocol for stimulation, in younger and older infertile population. Methods: This prospective analysis compiled data of 66 females, receiving ICSI treatment from April 2016 to October 2017. Serum FSH, LH, Estad...

Relationship Between Plasma Concentration of Hydroxyprogesterone Caproate (17-OHPC) and Preterm Birth
https://clinicaltrials.gov/ct2/show/NCT03292731

Jun 25th, 2018 - The study will determine the association between plasma concentrations of 17-OHPC (hydroxyprogesterone caproate) and the rate of preterm birth and will evaluate the impact of several potential covariates on plasma concentrations of 17-OHPC and its efficacy. 17-OHPC (hydroxyprogesterone caproate) administration has proven effective in reducing preterm births in high risk groups but the current d...

Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome
https://clinicaltrials.gov/ct2/show/NCT00968708

May 1st, 2014 - Alogliptin is a selective and potent dipeptidyl peptidase-4 inhibitor developed by Takeda for use in patients with type 2 diabetes mellitus. Cardiovascular outcomes is of special interest in the type 2 diabetes mellitus population, particularly in type 2 diabetes mellitus patients who have cardiovascular disease and are at high risk for major adverse cardiac events, such as those patients who h...

A Phase IIb Trial of Pulmicort Turbuhaler (Budesonide)
https://clinicaltrials.gov/ct2/show/NCT00175747

Sep 14th, 2005 - Studies in animals suggest that inhaled budesonide may prevent the occurrence of lung cancer. We conducted a clinical trial to determine the effects of inhaled budesonide in smokers who had precancerous lesions in the breathing tubes (i.e. bronchial dysplasia.

Hormone Replacement Therapy and Anti-HIV Drugs in HIV-Infected, Postmenopausal Women
https://clinicaltrials.gov/ct2/show/NCT00044837

Jun 3rd, 2015 - The benefits of hormone replacement therapy (HRT) in HIV-negative postmenopausal women include the abatement of menopausal symptoms such as hot flashes, insomnia, mood changes, vaginal dryness, urogenital and skin changes, and memory loss. HRT may also decrease risk for primary cardiovascular disease, osteoporosis, colon cancer, and possibly Alzheimer's disease and age-related macular degenerat...

Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes
https://clinicaltrials.gov/ct2/show/NCT01204775

Apr 17th, 2017 - The purpose of this study is to evaluate the efficacy, safety, tolerability, of Saxagliptin in pediatric patients with type 2 diabetes.

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
https://clinicaltrials.gov/ct2/show/NCT00558519

Jul 11th, 2017 - RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. PURPOSE: This phase II trial is studying how well combination chemotherapy works in treating young patients with newly diagnosed acute lymphoblastic leukemia.

Dexamethasone and Supportive Care With or Without Whole-Brain Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer That Has Spread to the Brain and Cannot Be Removed By Surgery
https://clinicaltrials.gov/ct2/show/NCT00403065

Aug 25th, 2013 - OBJECTIVES: Primary Compare the efficacy of dexamethasone with vs without whole-brain radiotherapy in combination with optimal supportive care, in terms of patient assessed quality adjusted life years, in patients with inoperable brain metastases secondary to non-small cell lung cancer. Secondary Compare the overall survival of patients treated with these regimens. Assess the Karnofsky performa...

Two Cycles of PAD Combination by AHCT in MM
https://clinicaltrials.gov/ct2/show/NCT01370434

Jun 9th, 2011 - 1.PAD combination chemotherapy Bortezomib 1.3 mg/m2 will be given by intravenous bolus injection on days 1, 4, 8, 11 of each cycle. Oral or intravenous dexamethasone 40 mg will be administered on days 1-4 and 8-11 with doxorubicin 9 mg/m2 by intravenous bolus on days 1-4 of each cycle. The cycle will be repeated every 3 weeks. A total of 2 cycles is planed before AHCT. For mobilization, G-CSF 1...

The Safety,Preliminary Pharmacodynamics and Pharmacokinetics Study of rExenatide-4 in Chinese Type 2 Diabetes Mellitus
https://clinicaltrials.gov/ct2/show/NCT01342042

This research is randomized, controlled trial. 36 Chinese subjects with Type 2 Diabetes Mellitus will take part in the trial. Subjects will randomly enter into one of three groups, administration daily twice, the period of is 84 days treatment. Subjects should be in hospital for pharmacokinetic studies in 1 d~ 8d, 30 d (if necessary)and 84 d, during 9 d ~ 83 d outpatient follow-up.

Comparison Between Systemic Exposure to Ciclesonide Nasal Spray, Ciclesonide HFA Nasal Aerosol and Orally Inhaled Ciclesonide (BY9010/M1-422)
https://clinicaltrials.gov/ct2/show/NCT00458835

Dec 1st, 2016 - The purpose of this study is to compare the systemic des-ciclesonide exposure of OMNARIS™ (ciclesonide) nasal spray, ciclesonide HFA nasal aerosol, and orally inhaled ciclesonide HFA-metered-dose inhaler (MDI). The administration of the study medication will be as follows: three single doses, separated by a wash-out period. The study will provide further data on the safety and tolerability of c...

Study of Difluprednate Ophthalmic Emulsion in the Treatment of Postoperative Inflammation
https://clinicaltrials.gov/ct2/show/NCT00407225

Dec 5th, 2006 - The objective is to assess the efficacy and safety of 0.002% and 0.05% difluprednate ophthalmic emulsions in patients with postoperative inflammation after cataract surgery (implantation of intraocular lens). In addition, the evaluation system for a future dose-finding phase III study of difluprednate ophthalmic emulsion will be established.